Invenra

Executive Summary

Invenra is a Madison, Wisconsin-based biotechnology company specializing in the discovery and development of novel multi-specific antibody therapeutics. Founded in 2011, the company leverages its proprietary B-Body® platform to generate high-yield, CMC-ready bispecific and trispecific antibodies. Invenra operates through a hybrid model, advancing its own oncology pipeline while also offering discovery and expression services to partners. This dual approach allows the company to generate revenue through service agreements while building long-term value through its internal programs. The B-Body® platform is designed to address key challenges in multi-specific antibody development, including production yields and manufacturability, positioning Invenra as a potential player in the rapidly evolving field of complex biologics. However, as a private company with limited public information, Invenra's progress and valuation remain opaque, and its ability to secure partnerships and advance its pipeline will be critical for future growth.

Upcoming Catalysts (preview)

• TBDAnnouncement of a major partnership or licensing deal for the B-Body platform60% success
• TBDDisclosure of preclinical data or IND filing for a lead internal candidate40% success
• TBDSeries B or other significant financing round50% success